AU2003237347B2 - Treatment of cell proliferative disorders with chlorotoxin - Google Patents

Treatment of cell proliferative disorders with chlorotoxin Download PDF

Info

Publication number
AU2003237347B2
AU2003237347B2 AU2003237347A AU2003237347A AU2003237347B2 AU 2003237347 B2 AU2003237347 B2 AU 2003237347B2 AU 2003237347 A AU2003237347 A AU 2003237347A AU 2003237347 A AU2003237347 A AU 2003237347A AU 2003237347 B2 AU2003237347 B2 AU 2003237347B2
Authority
AU
Australia
Prior art keywords
cancer
chlorotoxin
seq
peptide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003237347A
Other languages
English (en)
Other versions
AU2003237347A1 (en
Inventor
Vernon L. Alvarez
Matthew A. Gonda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transmolecular Inc
Original Assignee
Transmolecular Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transmolecular Inc filed Critical Transmolecular Inc
Publication of AU2003237347A1 publication Critical patent/AU2003237347A1/en
Application granted granted Critical
Publication of AU2003237347B2 publication Critical patent/AU2003237347B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2003237347A 2002-05-31 2003-06-02 Treatment of cell proliferative disorders with chlorotoxin Ceased AU2003237347B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38417102P 2002-05-31 2002-05-31
US60/384,171 2002-05-31
US40603302P 2002-08-27 2002-08-27
US60/406,033 2002-08-27
PCT/US2003/017411 WO2003101475A1 (en) 2002-05-31 2003-06-02 Treatment of cell proliferative disorders with chlorotoxin

Publications (2)

Publication Number Publication Date
AU2003237347A1 AU2003237347A1 (en) 2003-12-19
AU2003237347B2 true AU2003237347B2 (en) 2009-07-23

Family

ID=29715313

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003237347A Ceased AU2003237347B2 (en) 2002-05-31 2003-06-02 Treatment of cell proliferative disorders with chlorotoxin
AU2003240496A Expired AU2003240496B2 (en) 2002-05-31 2003-06-02 Combination chemotherapy with chlorotoxin

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2003240496A Expired AU2003240496B2 (en) 2002-05-31 2003-06-02 Combination chemotherapy with chlorotoxin

Country Status (10)

Country Link
US (1) US20060166892A1 (https=)
EP (4) EP2182004A1 (https=)
JP (3) JP2005537234A (https=)
AT (1) ATE458751T1 (https=)
AU (2) AU2003237347B2 (https=)
CA (2) CA2494451A1 (https=)
DE (1) DE60331458D1 (https=)
ES (1) ES2341767T3 (https=)
MX (1) MXPA04011871A (https=)
WO (2) WO2003101474A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060088899A1 (en) * 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
WO2005053611A2 (en) * 2003-11-26 2005-06-16 Transmolecular, Inc. Treatment of phosphatidylinositol phospholipid disorders
AU2005232616A1 (en) * 2004-04-06 2005-10-27 Transmolecular, Inc. Diagnosis and treatment of myeloid and lymphoid cell cancers
DE602006020710D1 (de) 2005-04-22 2011-04-28 Fred Hutchinson Cancer Res Foundation Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs
CA2647907A1 (en) * 2006-03-31 2007-10-18 Transmolecular, Inc. Use of tm-601 for the diagnosis and treatment of tumors
US8106013B2 (en) 2006-05-19 2012-01-31 Georgia Tech Research Corporation ABC transporter ligand GATX1
CN100590130C (zh) * 2007-07-31 2010-02-17 厦门北大之路生物工程有限公司 抗癌活性肽
EP2173385A1 (en) * 2007-08-07 2010-04-14 Transmolecular, Inc. Chlorotoxins as drug carriers
US20100215575A1 (en) * 2007-10-12 2010-08-26 Transmolecular, Inc. Systemic Administration of Chlorotoxin Agents for the Diagnosis and Treatment of Tumors
CN102438646A (zh) * 2008-05-15 2012-05-02 特兰斯莫莱库拉公司 转移性肿瘤的治疗
CA2724384A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
WO2010086964A1 (ja) * 2009-01-28 2010-08-05 株式会社 静岡カフェイン工業所 がん治療のための併用療法
CN102844044B (zh) 2010-02-04 2016-10-26 摩尔弗泰克有限公司 氯毒素多肽和结合物及其应用
EP3165533B1 (en) 2010-05-11 2020-04-08 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates and methods for their use
CU24055B1 (es) * 2010-09-27 2014-12-26 Grupo Empresarial De Producciones Biofarmacéuticas Y Químicas Labiofam Composiciones farmacéuticas de veneno de escorpión rhopalurus junceus
GB201106004D0 (en) 2011-04-08 2011-05-25 Univ Edinburgh Optical imaging probes
WO2013003507A1 (en) 2011-06-27 2013-01-03 Morphotek, Inc. Multifunctional agents
KR20150050524A (ko) 2012-04-17 2015-05-08 메리맥 파마슈티컬즈, 인크. 비침습적 이미징을 위한 조성물 및 방법
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
CA2913029A1 (en) 2012-12-10 2014-06-19 Fred Hutchinson Cancer Research Center Lipocalin fusion partners
EP2986287A2 (en) * 2013-04-18 2016-02-24 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions (ctps 1 inhibitors, e.g. norleucine) for inhibiting t cell proliferation in a subject in need thereof
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
WO2015061592A1 (en) * 2013-10-23 2015-04-30 Merrimack Pharmaceuticals, Inc. Liposomes for non-invasive imaging and drug delivery
US9522114B1 (en) * 2014-03-27 2016-12-20 University Of South Florida Enhanced targeted drug delivery system via chitosan hydrogel and chlorotoxin
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
JP7042739B2 (ja) 2015-08-20 2022-03-28 イプセン バイオファーム リミティド 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法
TW202400181A (zh) 2015-08-21 2024-01-01 英商益普生生物製藥有限公司 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法
WO2017143259A1 (en) * 2016-02-19 2017-08-24 Dignity Health Antibody fusion protein and related compositions for targeting cancer
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer
KR101678393B1 (ko) 2016-08-25 2016-12-06 (주)넥스젠바이오텍 피부 세포 증식 효과가 증가한 전갈독 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선, 피부 탄력 증대 및 항노화 화장료 조성물
CN110402163A (zh) 2016-11-02 2019-11-01 易普森生物制药有限公司 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
CN111542345B (zh) 2017-09-15 2025-02-25 卫材公司 氯毒素剂及其用途
CA3086040A1 (en) 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5905027A (en) * 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0491007B1 (en) * 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
US5223253A (en) * 1989-09-28 1993-06-29 American Home Products Corporation Bovine vaccine compositions and method for preventing trichomonas infections using same
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
EP0922458A1 (en) * 1993-01-14 1999-06-16 Cancer Research Campaign Technology Limited Potentiation of temozolomide by an ATase inhibitor
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5756340A (en) * 1995-05-08 1998-05-26 The Regents Of The University Of California Insect control with multiple toxins
JP3809502B2 (ja) * 1995-05-30 2006-08-16 二郎 有川 ハンタウィルス抗原蛋白質およびモノクローナル抗体
JPH0971599A (ja) * 1995-09-06 1997-03-18 Nippon Seibutsu Kagaku Kenkyusho 鶏貧血ウイルス（ｃａｖ）感染鶏血清と高い反応性を示すポリペプチド及びこのポリペプチドに対する抗体、鶏貧血ウイルス感染の診断法及びワクチン
US6667156B2 (en) * 1995-12-27 2003-12-23 Uab Research Foundation Diagnosis and treatment of neuroectodermal tumors
US6555652B1 (en) * 1997-12-05 2003-04-29 Kyogo Itoh Tumor antigen peptide derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5905027A (en) * 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
US6028174A (en) * 1995-12-27 2000-02-22 Uab Research Foundation Method of diagnosing and treating gliomas
US20020065216A1 (en) * 1995-12-27 2002-05-30 The Uab Research Foundation Novel method of diagnosing and treating gliomas

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LYONS S A ET AL, GLIA, vol. 39, no. 2, 29 May 2002, pages 162-173 *
SOROCEANU L ET AL, CANCER RESEARCH, vol. 58, no. 21, 1 November 1998, pages 4871-4879 *

Also Published As

Publication number Publication date
DE60331458D1 (de) 2010-04-08
JP2005537234A (ja) 2005-12-08
ES2341767T3 (es) 2010-06-28
EP1553962A4 (en) 2008-01-02
CA2494451A1 (en) 2003-12-11
EP1553962A1 (en) 2005-07-20
EP1553962B1 (en) 2010-02-24
AU2003237347A1 (en) 2003-12-19
JP5856744B2 (ja) 2016-02-10
MXPA04011871A (es) 2005-07-26
EP1539207A4 (en) 2008-01-02
EP2431385A3 (en) 2012-07-04
WO2003101474A1 (en) 2003-12-11
JP2015214562A (ja) 2015-12-03
US20060166892A1 (en) 2006-07-27
EP2182004A1 (en) 2010-05-05
WO2003101475A1 (en) 2003-12-11
EP2431385A2 (en) 2012-03-21
CA2487425A1 (en) 2003-12-11
ATE458751T1 (de) 2010-03-15
JP2011153149A (ja) 2011-08-11
EP1539207A1 (en) 2005-06-15
AU2003240496B2 (en) 2008-01-10
AU2003240496A1 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
AU2003237347B2 (en) Treatment of cell proliferative disorders with chlorotoxin
US20100210546A1 (en) Combination chemotherapy with chlorotoxin
JP2011149961A (ja) 骨髄およびリンパ系細胞癌の診断および処置
KR20160089523A (ko) 전립선 암 치료용 조성물
DK2567983T3 (en) A TUMOR-TARGETING TNF-RELATED apoptosis inducing LIGANDVARIANT AND USE THEREOF
JP7495390B2 (ja) Ｆｇｆｒ１変異陽性脳腫瘍を治療するための医薬組成物及び治療方法
AU2001288405B8 (en) Amino acid substitution mutants of interleukin 13
Kawakami et al. Gene transfer of interleukin 13 receptor α2 chain dramatically enhances the antitumor effect of IL-13 receptor–targeted cytotoxin in human prostate cancer xenografts
US20100210829A1 (en) Compositions and Methods for Treating Diseases, Disorders, or Conditions Characterized by Myelin Degeneration, Myelin Deficiency or Loss
CN108295242A (zh) 用于预防和/或治疗银屑病药物组合物、cd317胞外段蛋白的应用
AU2016271292B2 (en) An engineered CCL20 locked dimer polypeptide
US11571462B2 (en) Engineered CCL20 locked dimer polypeptide
US20250082734A1 (en) Ptprs in autoimmunity
CN111732631B (zh) 一种多肽及其在制备治疗和预防肿瘤的药物中的应用
WO2024169903A1 (zh) 诱导肝细胞去分化促进肝脏再生及缓解药物引起的肝损伤的方法及应用
HK1172630A (en) Combination therapy with chlorotoxin
EP3720467A1 (en) Methods for treatment of neuropathic pain

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN EXTENDED TO 31 JAN 2005.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired